Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 13:2021:6640594.
doi: 10.1155/2021/6640594. eCollection 2021.

Meta-Analysis of Clinical Efficacy and Safety of Tripterygium wilfordii Polyglycosides Tablets in the Treatment of Chronic Kidney Disease

Yan-Li Guo  1 , Feng Gao  1 , Tai-Wei Dong  1 , Yang Bai  2 , Qiao Liu  1 , Ruo-Lan Li  1 , Shu-Ting Yan  1 , Mei Chen  3 , Pei-Feng Wei  1   2 , Miao-Miao Xi  2
Affiliations
Review

Meta-Analysis of Clinical Efficacy and Safety of Tripterygium wilfordii Polyglycosides Tablets in the Treatment of Chronic Kidney Disease

Yan-Li Guo et al. Evid Based Complement Alternat Med. .

Abstract

Objective: Tripterygium wilfordii polyglycosides tablet (TGt) is an oral preparation extracted from plant Tripterygium wilfordii. It has the effects of anti-inflammation and inhibition of cellular and humoral immunity. However, many reports of adverse reactions caused by TGt have limited its application. In this paper, the clinical efficacy and safety of TGt in the treatment of chronic kidney disease (CKD) were verified by data mining and analysis, so as to provide theoretical data support for the application and development of TGt.

Methods: A computer search of the following databases was conducted: PubMed, Web of Science, CBM, VIP, Wanfang Data, and CNKI. The search time limit is from the establishment of the database to September 2020. We searched for clinical randomized controlled trials of TGt in the treatment of CKD. The main types of CKD involved are nephrotic syndrome (NS), primary nephrotic syndrome (PNS), refractory nephrotic syndrome (RNS), and IgA nephropathy (IgAN). RevMan 5.2 and Stata 12.0 software were used to evaluate the literature quality and analyze the data. Finally, GRADEpro software was used to evaluate the quality of evidence.

Results: According to the inclusion and exclusion criteria, 75 articles with a total of 6418 subjects were included. The results of the meta-analysis showed that TGt could reduce 24-hour urinary protein, increase serum albumin, improve clinical efficacy, and reduce disease recurrence rate in patients (P < 0.05) with CKD compared with adrenocortical hormones or immunosuppressants. TGt could significantly reduce the level of serum creatinine (Scr) in patients with CKD (P < 0.05), but it was not significant in reducing the level of blood urea nitrogen (P > 0.05). In terms of safety evaluation, in patients with CKD, it could significantly reduce the incidence of gastrointestinal adverse reactions and neurogenic dizziness and headache (P < 0.05). However, in terms of adverse reactions such as liver injury, respiratory infection, and leukopenia, TGt was as harmful as corticosteroids or immunosuppressants (P < 0.05). The quality of the evidence was evaluated with GRADEpro software, and the results showed that TGt was strongly recommended for the treatment of CKD.

Conclusion: TGt has certain efficacy in the treatment of CKD and has fewer side effects in certain types of diseases. The effect of TGt combined with other drugs is better than that of single use. This paper also has some limitations. Due to the limited number of the included studies, with all being from China, there may be methodological differences. Therefore, more high-quality literature data from different countries are needed.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Results of literature screening.
Figure 2
Figure 2
The literature is included in the quality evaluation map.
Figure 3
Figure 3
Comparison of clinical efficacy of different types of diseases between the experimental group and the control group.
Figure 4
Figure 4
Comparison of recurrence between the experimental group and control group.
Figure 5
Figure 5
Comparison of 24-hour urinary protein in patients with different types of diseases between the experimental group and the control group.
Figure 6
Figure 6
Comparison of serum creatinine level of drug intervention between the experimental group and control group with different types of diseases.
Figure 7
Figure 7
Comparison of drug intervention on blood urea nitrogen between the experimental group and control group of different types of diseases.
Figure 8
Figure 8
Comparison of drug intervention on serum albumin between the experimental group and the control group with different types of diseases.
Figure 9
Figure 9
Comparison of adverse reactions caused by drugs in different types of experimental group and control group.
Figure 10
Figure 10
Comparison of gastrointestinal adverse reactions induced by drugs in different types of diseases between the experimental group and the control group.
Figure 11
Figure 11
Comparison of the intervention of drugs on leukopenia between the experimental group and the control group.
Figure 12
Figure 12
Comparison of liver injury induced by drugs in the experimental group and the control group.
Figure 13
Figure 13
Comparison of respiratory tract infection caused by drugs in the experimental group and the control group.
Figure 14
Figure 14
Comparison of dizziness and headache caused by drugs in the experimental group and the control group.
Figure 15
Figure 15
Comparison of the increase of blood glucose induced by drugs in the experimental group and the control group.
Figure 16
Figure 16
Evaluation of evidence quality of outcome indicators of TGt in the treatment of chronic nephropathy.
See this image and copyright information in PMC

References

    1. Stevens L. A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of Internal Medicine. 2013;158:p. 11. - PubMed
    1. Vivekanand J G. G., Kunitoshi I., et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382:p. 9888. - PubMed
    1. Jankowska M C. G., Lindholm B., et al. Inflammation and protein-energy wasting in the uremic milieu. Contrib Nephrol. Contributions to Nephrology. 2018;191:58–71. - PubMed
    1. Zha Q. Q. Protein nutrition and malnutrition in CKD and ESRD. Nutrients. 2014;3(9):34–35. - PMC - PubMed
    1. Jiang X. S., Lv D., et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Science Report. 2016;1(7):p. 2870. - PMC - PubMed

LinkOut - more resources